Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Day One Biopharmaceuticals Community
NasdaqGS:DAWN Community
1
Narratives
written by author
0
Comments
on narratives written by author
8
Fair Values set
on narratives written by author
Create a narrative
Day One Biopharmaceuticals
Popular
Undervalued
Overvalued
Community Investing Ideas
Day One Biopharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Pediatric Oncology Adoption And Pipeline Expansion Will Drive Future Success
Key Takeaways Expanding adoption of OJEMDA and a growing clinical pipeline position the company for sustained revenue growth and reduced reliance on a single product. International regulatory progress and strong payer support enable broader market access, improved margins, and financial flexibility for further investment.
View narrative
US$26.25
FV
72.5% undervalued
intrinsic discount
36.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
about 21 hours ago
author updated this narrative
Your Valuation for
DAWN
DAWN
Day One Biopharmaceuticals
Your Fair Value
US$
Current Price
US$7.21
43.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-209m
578m
2015
2018
2021
2024
2025
2027
2030
Revenue US$578.0m
Earnings US$117.3m
Advanced
Set Fair Value